Although the present study failed to observe PFS benefit of EGFR-TKI plus bevacizumab in EGFR-mutant NSCLC, the OS outcome was significantly improved in patients receiving the regimen. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.